197 related articles for article (PubMed ID: 25261291)
41. A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy.
Sohn BS; Jeong JH; Ahn JH; Jung KH; Kim JE; Sohn JH; Koh SJ; Seo JH; Lee KS; Kim SB
Invest New Drugs; 2020 Jun; 38(3):866-873. PubMed ID: 31728715
[TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetics and pharmacodynamics of pegfilgrastim.
Yang BB; Kido A
Clin Pharmacokinet; 2011 May; 50(5):295-306. PubMed ID: 21456630
[TBL] [Abstract][Full Text] [Related]
43. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
Crawford J
Semin Oncol; 2003 Aug; 30(4 Suppl 13):24-30. PubMed ID: 14508717
[TBL] [Abstract][Full Text] [Related]
44. Factors Associated with Absolute Neutrophil Count Dynamics and Docetaxel-Adryamicin-Cyclophosphamide (TAC) Chemotherapy Induced Neutropenia During Extended Filgrastim Administration in Breast Cancer Patients.
Ashariati A; Bintoro UY; Savitri M; Diansyah MN; Amrita PNA; Romadhon PZ; Wijaya AY; Hendrata WM; Looi SS; Mahmudin AA
Acta Med Indones; 2022 Jul; 54(3):371-378. PubMed ID: 36156473
[TBL] [Abstract][Full Text] [Related]
45. Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
Blackwell K; Gascon P; Jones CM; Nixon A; Krendyukov A; Nakov R; Li Y; Harbeck N
Ann Oncol; 2017 Sep; 28(9):2272-2277. PubMed ID: 28637287
[TBL] [Abstract][Full Text] [Related]
46. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
[TBL] [Abstract][Full Text] [Related]
47. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
Vose JM; Crump M; Lazarus H; Emmanouilides C; Schenkein D; Moore J; Frankel S; Flinn I; Lovelace W; Hackett J; Liang BC
J Clin Oncol; 2003 Feb; 21(3):514-9. PubMed ID: 12560443
[TBL] [Abstract][Full Text] [Related]
48. Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
Blackwell K; Semiglazov V; Krasnozhon D; Davidenko I; Nelyubina L; Nakov R; Stiegler G; Singh P; Schwebig A; Kramer S; Harbeck N
Ann Oncol; 2015 Sep; 26(9):1948-1953. PubMed ID: 26122726
[TBL] [Abstract][Full Text] [Related]
49. Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis.
Ngamphaiboon N; O'Connor TL; Advani PP; Levine EG; Kossoff EB
Med Oncol; 2012 Sep; 29(3):1495-501. PubMed ID: 21818673
[TBL] [Abstract][Full Text] [Related]
50. Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.
Bond TC; Szabo E; Gabriel S; Klastersky J; Tomey O; Mueller U; Schwartzberg L; Tang B
J Oncol Pharm Pract; 2018 Sep; 24(6):412-423. PubMed ID: 28614980
[TBL] [Abstract][Full Text] [Related]
51. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.
del Giglio A; Eniu A; Ganea-Motan D; Topuzov E; Lubenau H
BMC Cancer; 2008 Nov; 8():332. PubMed ID: 19014494
[TBL] [Abstract][Full Text] [Related]
52. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy.
Crawford J
Pharmacotherapy; 2003 Aug; 23(8 Pt 2):15S-19S. PubMed ID: 12921218
[TBL] [Abstract][Full Text] [Related]
53. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
Shi YK; He XH; Yang S; Wang HQ; Jiang ZF; Zhu YZ; Ke XY; Zhang Y; Liu YP; Zhang WJ; Wang Z; Shi QZ; Xie XD; Zhang HL; Wang JJ; Luo DY; Zheng QS; Sun RY
Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3414-9. PubMed ID: 17313855
[TBL] [Abstract][Full Text] [Related]
54. The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies.
Whitworth JM; Matthews KS; Shipman KA; Numnum TM; Kendrick JE; Kilgore LC; Straughn JM
Gynecol Oncol; 2009 Mar; 112(3):601-4. PubMed ID: 19110303
[TBL] [Abstract][Full Text] [Related]
55. A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial.
Sierra J; Szer J; Kassis J; Herrmann R; Lazzarino M; Thomas X; Noga SJ; Baker N; Dansey R; Bosi A
BMC Cancer; 2008 Jul; 8():195. PubMed ID: 18616811
[TBL] [Abstract][Full Text] [Related]
56. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia.
Crawford J
Drugs; 2002; 62 Suppl 1():89-98. PubMed ID: 12479597
[TBL] [Abstract][Full Text] [Related]
57. A modified filgrastim regimen does not reduce pain burden compared to pegfilgrastim in women receiving chemotherapy for non-metastatic breast cancer.
Leung M; Florendo J; Kano J; Marr-Del Monte T; Higgins B; Myers R; Menon T; Jones G
Support Care Cancer; 2015 Jun; 23(6):1669-77. PubMed ID: 25421443
[TBL] [Abstract][Full Text] [Related]
58. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
Perrier L; Lefranc A; PĂ©rol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
[TBL] [Abstract][Full Text] [Related]
59. Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer.
Kourlaba G; Dimopoulos MA; Pectasides D; Skarlos DV; Gogas H; Pentheroudakis G; Koutras A; Fountzilas G; Maniadakis N
Support Care Cancer; 2015 Jul; 23(7):2045-51. PubMed ID: 25524005
[TBL] [Abstract][Full Text] [Related]
60. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.
Lane SW; Crawford J; Kenealy M; Cull G; Seymour JF; Prince HM; Marlton P; Gill D; Mollee PN
Leuk Lymphoma; 2006 Sep; 47(9):1813-7. PubMed ID: 17064993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]